The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease

H. Rao1 | E. Wu2 | S. Fu2 | M. Yang1 | B. Feng1 | A. Lin3 | R. Fei1 | R. J. Fontana2 | A. S. Lok2 | L. Wei1

1Peking University Hepatology Institute, Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
2Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
3The Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA

Correspondence
Prof. L. Wei, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People’s Hospital, Beijing, China.
Email: weilai@pkuph.edu.cn

Funding Information
This study was supported by the University of Michigan Health System and Peking University Health Science Center Joint Institute for Clinical and Translational Research (grant number: BMU20110175) & Bristol-Myers Squibb Foundation (grant number: AI452-104)

Summary
Background: Chronic hepatitis C virus (HCV) infection is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) in the United States (US) and an emerging cause in China.
Aim: To compare the clinical characteristics of hepatitis C patients in the US and China, and factors influencing disease stage.
Methods: Prospective study of 2 cohorts of HCV patients recruited at 1 site in the US and 3 sites in China. Standardised questionnaire on risk factors and medical history were used and diagnosis of cirrhosis and HCC was based on pre-defined criteria.
Results: One thousand nine hundred and fifty seven patients (1000 US and 957 China) were enrolled. US patients were more likely to be men (61.4% vs 48.5%), older (median age 57 vs 53 years), obese (38.4% vs 16.8%) and diabetic (21.8% vs 10.8%). A significantly higher percent of US patients had cirrhosis (38.2% vs 16.0%) and HCC (14.1% vs 2.7%). Investigator estimated time at infection in US was 10 years earlier than in Chinese patients but US patients were more likely to have advanced disease even after stratifying for duration of infection. Study site in the US, older age, truncal obesity, diabetes and prior HCV treatment were significant predictors of advanced disease on multivariate analysis.
Conclusions: HCV patients in the US had more advanced liver disease than those in China. We speculate that underlying fatty liver disease may be a major contributor to this difference, and management of glycometabolic abnormalities should occur in parallel with anti-viral therapy to achieve optimal outcomes.
Chronicle hepatitis C virus (HCV) infection is a major global health problem. Worldwide, more than 185 million people have been infected with HCV, of whom 350 000 die each year. The prevalence of chronic HCV infection is estimated to be 1.5% in the United States (US) based on National Health and Nutrition Examination Survey; however, the actual prevalence is likely much higher with at least 3.5 million Americans chronically infected. In China, the prevalence of chronic HCV infection is estimated at 1%-1.9%, affecting roughly 25 million people representing nearly 15% of the total HCV-infected population worldwide. Chronic HCV infection is the leading cause of cirrhosis and HCC in the US and many western countries. In the US, HCV is estimated to account for 33.9% of HCC. In China, chronic hepatitis B virus (HBV) infection had been the predominant cause of HCC; however, with the success of hepatitis B vaccination programmes, chronic HCV infection has become an increasingly important cause of HCC with recent estimates showing 5.2% of HCC is due to HCV.

Cirrhosis develops in roughly 20% of persons with chronic HCV infection after 20 years of infection. However, progression of HCV-related liver disease is variable with roughly 22% of liver clinic patients and 24% of patients in post-transfusion studies but only 4%-7% of patients in community-based studies developing cirrhosis after 20 years of infection. In a cohort of Chinese paid plasma donors, we followed up for a median of 17 years, the incidence of liver cirrhosis was 10.0%, HCC 2.9%, and overall mortality 8.2%. Host (genetics, obesity, diabetes), virus (duration of HCV infection, HCV genotype, coinfection with HBV or human immunodeficiency virus [HIV]), and environmental (alcohol, smoking, coffee) factors contribute to progression of hepatitis C. The contribution of each of these factors to cirrhosis and HCC may be different in different countries. Obesity and diabetes are more common in American patients while coinfection with HBV is more prevalent among Chinese patients. Coffee consumption which has been shown to have a protective effect on liver disease including HCC is more common in American patients. These differences and differences in timing of the peak of HCV epidemic in the two countries may contribute to differences in disease progression and burden of HCV-related liver disease in the US and China.

This study was designed to compare the epidemiologic and clinical characteristics, the stage of liver diseases, and the factors associated with advanced liver disease (cirrhosis or HCC) in two cohorts of adult patients with chronic HCV infection in the US and China.

2 | MATERIALS AND METHODS

2.1 | Study design and patients

This was a prospective study of two parallel cohorts of patients with chronic HCV infection recruited in Ann Arbor, US (University of Michigan Health System, UMHS) and in Beijing, China (Peking University Health Science Center, PUHSC). Patients in China were enrolled from three sites: Peking University People’s Hospital in Beijing, and Gu’an and Kuancheng clinics in Hebei. The PUHSC team has been providing care for hepatitis C patients in Hebei which is a rural area 45 miles from Beijing, since 2002. Most patients in Gu’an were initially identified from the community during investigation of outbreaks of HCV in paid plasma donors while patients in Beijing and Kuancheng presented to liver clinics for investigation of abnormal liver chemistries or clinical manifestations of liver disease, or after diagnosis of hepatitis C.

The inclusion criteria were: adult patients (≥18 years old) with chronic HCV infection (HCV RNA positive). Patients who had undergone liver transplantation, known coinfection with HIV, life expectancy <12 months due to extra-hepatic illnesses, or were receiving HCV treatment at enrolment, were excluded. Patients enrolled in both countries were evaluated using an identical protocol. Protocol, surveys, and data forms were developed in English and then translated into Chinese and the accuracy of translation verified by UMHS investigators fluent in Chinese. Each patient enrolled in both countries completed the same questionnaire at enrolment. A web-based database with both English and Chinese versions was created and accessible to both teams and data uploaded every night and stored at a UMHS server.

All patients provided written informed consent before enrolment in the study. The study was approved by the institutional review board or ethics committee at both the University of Michigan and Peking University, the latter provides regulatory oversight for studies done at the Hebei sites, and complied with the provisions of Good Clinical Practice.

2.2 | Clinical parameters

Demographic (race/ethnicity, age, gender), clinical (medical history, current medications, and family history of liver disease and HCC), and laboratory data (blood counts, liver panel, creatinine, international normalised ratio [INR], alpha fetoprotein, HCV genotype, HCV RNA, hepatitis B surface antigen [HBsAg], antibody to hepatitis B core antigen [anti-HBc]), and abdominal imaging (ultrasound, computed tomography [CT], magnetic resonance imaging [MRI]), liver elastography and liver histology results were collected through structured history taking and medical record review. Risk factors for HCV infection, and alcohol, tobacco and coffee consumption were assessed using a standardised questionnaire. Total alcohol consumption over a lifetime was defined as none-minimal (<1 drink/day × 1 year, ie, <365 total drinks), moderate (365-3650 total drinks, ie, up to 2 drinks/day × 5 years in women and 365-5475 total drinks, ie, up to 3 drinks/day × 5 years in men) and heavy (>3650 total drinks for women and >5475 total drinks for men). Tobacco use was defined as never smoked, ≤10 pack-years, 10-20 pack-years and >20 pack-years. Regular coffee consumption was defined as at least 1 cup/day.

2.3 | Assessment of advanced liver disease

Patients were categorised as having chronic hepatitis, cirrhosis or HCC. Patients meeting criteria for diagnosis of cirrhosis or HCC were considered to have advanced liver disease.
Standardised criteria for diagnosis of cirrhosis and HCC were used at both centres. Diagnosis of cirrhosis was based on histology when available. In the absence of biopsy results, diagnosis of cirrhosis was based on evidence of clinical decompensation or 2 of the following 4 criteria: radiological imaging showing features of cirrhosis (nodular liver, intra-abdominal varices or splenomegaly), platelet count <1000/μL in the absence of other explanations, liver stiffness measurement >13 kPa, and gastro-oesophageal varices on endoscopy.

HCC was diagnosed by histology wherever possible and in the absence of histology, by triple phase CT or MRI per the American Association for the Study of Liver Diseases guidelines.14

Source documents supporting the diagnosis of cirrhosis and HCC were collected and investigators from each country audited the documents from the other country to confirm these diagnoses.

2.4 Definition of diabetes and obesity

Diabetes was defined by medical history or use of medications for treatment of diabetes; and for those with no history of diabetes by fasting blood glucose≥126 mg/dL or random blood glucose ≥200 mg/dL.15,16 Obesity was defined using race adjusted cutoff for body mass index (BMI) and waist circumference (WC).17 For Americans, overweight was defined as BMI 25-30, and obese as BMI ≥30 kg/m2. For Chinese patients, overweight was defined as BMI 24-28, and obese as BMI ≥28 kg/m2. Truncal obesity was defined as WC ≥102 cm for male or ≥88 cm for female American patients, and WC ≥90 cm for male or ≥85 cm for female Chinese patients.

2.5 Statistical analysis

Data were downloaded from the UMHS server and analysed using Statistical Package for the Social Science (IBM spss version 20.0). Non-parametric Mann-Whitney test or Kruskal-Wallis test was used for comparison of continuous variables and Chi-squared test for comparison of categorical data. Multivariate logistic regression models were built to identify independent factors associated with advanced liver disease (cirrhosis and HCC) for each cohort and for the combined cohort. Demographic, clinical and environmental factors with P < 1 on univariate analysis were incorporated in the full model and the final model was derived by backward selection. P < .05 were considered statistically significant.

3 RESULTS

3.1 Characteristics of the two cohorts in the US and China

A total of 1957 patients were enrolled (1000 at UMHS and 957 at PUHSC including 428 in Beijing, 387 in Gu’an and 142 in Kuancheng) between September 2011 and July 2015. During the study period, 335 patients at UMHS and 92 patients at PUHSC met eligibility criteria but were not enrolled (Figure S1). Baseline characteristics of patients enrolled did not differ from those not enrolled.

US patients were more likely to be men (61.4% vs 48.5%) and to be older, median age 57 vs 53 years (Table 1). The most common modes of transmission were injection drug use and blood transfusion in US patients, and blood transfusion and medical procedures in Chinese patients. US patients were significantly more likely to be obese by BMI and to have truncal obesity than Chinese patients (obese, 38.4% vs 16.8%; truncal obesity, 59.8% vs 44.2%). A significantly higher per cent of US patients had diabetes (21.8% vs 10.8%) and hypertension (42.2% vs 27.4%).

US patients were more likely to be current/past drinkers (62.9% vs 27.9%) or smokers (78.9% vs 35.7%), and to consume coffee regularly (62.6% vs 5.1%) than Chinese patients. US patients were less likely to be anti-HBc positive (32.0% vs 46.4%) than Chinese patients. Only 0.2% US and 2.3% Chinese patients were HBSAg positive.

A significantly higher per cent of US patients had received prior HCV treatment, 44.1% compared to 21.7% of Chinese patients. Genotype 1 was most common in both cohorts (83.6% US and 71.1% China); however, while most patients in the US with genotype 1 had subtype 1a, subtype 1a was rare in China.

The three groups of patients enrolled in China differed in many respects (Table 1 and Table S1). Patients in Gu’an were more likely to be obese by BMI and by waist circumference but patients in Beijing were more likely to have diabetes. Patients in Kuancheng were more likely to be current/past drinkers or smokers while patients in Beijing were more likely to regularly consume coffee. Patients in Kuancheng had the highest prevalence of anti-HBc while patients in Beijing were most likely to have received HCV treatment in the past.

3.2 Prevalence of advanced liver disease in the US and Chinese cohorts

The US cohort included 477 (47.7%) patients with chronic hepatitis, 382 (38.2%) with cirrhosis and 141 (14.1%) with HCC; while the Chinese cohort included 778 (81.3%) patients with chronic hepatitis, 153 (16.0%) with cirrhosis and 26 (2.7%) with HCC. Among the patients with cirrhosis, diagnosis was based on histology, clinical decompensation, and other methods in 46.1%, 35.9%, and 18.1%, respectively in the US cohort, and in 2.6%, 27.5%, and 69.9%, respectively in the Chinese cohort. The US cohort included 109 decompensated patients had ascites, while the Chinese cohort included 40 decompensated patients had ascites.

A significantly higher per cent of US patients had advanced liver disease (cirrhosis or HCC) (52.3% vs 18.7%, P < .001). A significant difference was also observed when cirrhosis (38.2% vs 16.0%, P < .001) and HCC (14.1% vs 2.7%, P < .001) were analysed separately. In both cohorts, patients categorised as having advanced liver disease had higher aspartate aminotransferase to platelet ratio index (APRI) and higher Fibrosis index based on the 4 factors (FIB-4) (Table 2).
Factors associated with advanced liver disease

In both cohorts, patients with advanced liver disease were significantly older, more likely to have truncal obesity, diabetes and hypertension; and to have received prior HCV treatment, but similar use of alcohol and tobacco, compared to those without advanced liver disease (Table 2). Patients with advanced liver disease were more likely to be anti-HBc positive (US: 34.0% vs 29.8%, China: 55.3% vs 44.3%) but the difference was significant only in the Chinese cohort. While there were significant differences in sex, obesity by BMI and

| Characteristics | US cohort | Chinese cohort | P value | Beijing site | Gu’an site | Kuancheng site | P value |
|-----------------|-----------|----------------|---------|--------------|------------|---------------|---------|
| No. of patients | 1000      | 957            |         | 428          | 387        | 142           |         |
| Sex (men)       | 61.4      | 48.5           | <.001   | 47.2         | 46.5       | 57.8          | .056    |
| Age (y)         | 57 (19-80)| 53 (18-86)     | <.001   | 52 (18-86)   | 54 (24-84) | 52 (28-76)    | .805    |
| BMI (kg/m²)     | 28.2 (14.7-55.6) | 24.2 (14.8-49.6) | <.001 | 23.5 (14.8-49.6) | 25.2 (15.9-38.8) | 23.5 (17.3-33.3) | .534    |
| Waist circumference (cm) | 102.9 (66.0-161.3) | 85.0 (56.0-126.0) | <.001 | 84.0 (56.0-126.0) | 86.0 (60.0-120.0) | 85.0 (65.0-112.0) | .890    |
| Obesity by BMI  | 38.4      | 16.8           | <.001   | 12.9         | 24.3       | 8.5           | <.001   |
| Truncal obesity | 59.8      | 44.2           | <.001   | 39.3         | 49.4       | 45.1          | .015    |
| Hypertension    | 42.2      | 27.4           | <.001   | 27.6         | 28.4       | 23.9          | .588    |
| Diabetes        | 21.8      | 10.8           | <.001   | 15.4         | 7.8        | 4.9           | <.001   |
| Duration of infection (y) | 33.0 (0.0-56.0) | 23.0 (0.0-55.0) | <.001 | 23.0 (0.0-55.0) | 24.0 (2.0-50.0) | 24.0 (3.0-41.0) | .561    |
| Estimated y at infection | 1980 (1956-2014) | 1990 (1958-2013) | <.001 | 1990 (1958-2013) | 1990 (1961-2011) | 1990 (1973-2010) | .234    |
| Current/past alcohol use | 62.9 | 27.9 | <.001 | 21.7 | 29.2 | 43.0 | <.001 |
| Current/past smoking | 78.9 | 35.7 | <.001 | 26.6 | 42.4 | 45.1 | <.001 |
| Coffee consumption | 62.6 | 5.1 | <.001 | 10.3 | 1.3 | 0 | <.001 |
| HBsAg+          | 0.2       | 2.3            | <.001   | 2.3         | 1.6        | 4.2           | .191    |
| Anti-HBc+       | 32.0      | 46.4           | <.001   | 39.0         | 43.2       | 77.5          | <.001   |
| Liver disease category | <.001 | <.001 | | | | |
| Chronic hepatitis | 47.7 | 81.3 | 74.1 | 89.9 | 79.6 |
| Cirrhosis       | 38.2      | 16.0           |         | 21.0         | 9.8        | 17.6          |         |
| HCC             | 14.1      | 2.7            |         | 4.9          | 0.3        | 2.8           |         |
| Prior HCV treatment | 44.1 | 21.7 | <.001 | 31.8 | 11.4 | 19.7 | <.001 |
| HCV genotype    | <.001     | <.001          |         | <.001        | <.001      | <.001         |         |
| 1               | 83.6      | 69.1           | 63.4    | 77.7         | 62.5       |             |         |
| 1a              | 48.0      | 0.1            | 0.0     | 0.3          | 0.0        |             |         |
| 1b              | 20.2      | 67.0           | 61.5    | 74.8         | 61.8       |             |         |
| 1 not subtyped  | 15.4      | 2.0            | 1.9     | 2.6          | 0.7        |             |         |
| 2               | 5.9       | 25.4           | 26.8    | 21.8         | 30.9       |             |         |
| 3               | 8.6       | 2.2            | 5.0     | 0.0          | 0.0        |             |         |
| 4               | 1.8       | 0.0            | 0.0     | 0.0          | 0.0        |             |         |
| 5               | 0.0       | 0.0            | 0.0     | 0.0          | 0.0        |             |         |
| 6               | 0.0       | 0.5            | 1.2     | 0.0          | 0.0        |             |         |
| Mixed genotypes | 0.1      | 2.8            | 3.6     | 0.5          | 6.6        |             |         |
| Platelet (×1000/µL) | 146.0 (17.0-559.0) | 166.0 (23.0-390.0) | <.001 | 156.0 (25.0-390.0) | 174.0 (39.0-368.0) | 165.0 (23.0-363.0) | .343    |
| AST (U/L)       | 65.5 (5.9-480.0) | 40.5 (11.0-366.0) | <.001 | 40.0 (11.0-345.0) | 40.0 (15.0-366.0) | 43.0 (15.0-218.0) | .630    |
| ALT (U/L)       | 62.0 (9.0-989.0) | 43.0 (7.0-488.0) | <.001 | 41.0 (7.0-399.0) | 45.0 (10.0-488.0) | 44.5 (11.0-292.0) | .433    |
| Total bilirubin (mg/dL) | 0.7 (0.1-12.6) | 0.9 (0.3-14.1) | .008 | 0.9 (0.3-14.1) | 0.8 (0.3-3.0) | 1.0 (0.4-6.9) | .753    |
| INR             | 1.1 (0.6-3.7) | 1.0 (0.8-2.9) | <.001 | 1.0 (0.8-2.9) | 1.0 (0.8-1.4) | 1.0 (0.9-1.9) | .166    |

Data presented as median (range) for continuous variables or per cent for categorical variables.

BMI, body mass index; HBsAg, hepatitis B surface antigen; Anti-HBc, antibody to hepatitis B core antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalised ratio.

3.3 Factors associated with advanced liver disease

In both cohorts, patients with advanced liver disease were significantly older, more likely to have truncal obesity, diabetes and hypertension; and to have received prior HCV treatment, but similar use of alcohol and tobacco, compared to those without advanced liver disease (Table 2). Patients with advanced liver disease were more likely to be anti-HBc positive (US: 34.0% vs 29.8%, China: 55.3% vs 44.3%) but the difference was significant only in the Chinese cohort. While there were significant differences in sex, obesity by BMI and
### TABLE 2 Characteristics of patients with advanced liver disease (cirrhosis and HCC) and no advanced liver disease in the US and Chinese cohorts

| Characteristics | US | | | | China | | | |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Advanced liver disease | No advanced disease | P value | Advanced liver disease | No advanced disease | P value |
| No. of patients (%) | 523 (52.3) | 477 (47.7) | .033 | 179 (18.7) | 778 (81.3) | .297 |
| Sex (men) | 64.6 | 57.9 | <.001 | 58 (33-85) | 52 (18-86) | <.001 |
| Age (y) | 58 (20-80) | 55 (19-77) | <.001 | 58 (33-85) | 52 (18-86) | <.001 |
| BMI (kg/m²) | 28.8 (17.0-55.6) | 27.8 (14.7-50.8) | <.001 | 24.6 (16.6-38.3) | 24.2 (14.8-49.6) | .039 |
| Waist circumference (cm) | 105.4 (66.0-161.3) | 100.3 (66.0-149.9) | <.001 | 88.0 (66.0-126.0) | 84.0 (56.0-120.0) | <.001 |
| Obesity by BMI | 42.3 | 34.2 | <.001 | 19.0 | 16.3 | .453 |
| Truncal obesity | 64.6 | 54.5 | <.001 | 54.7 | 41.8 | .002 |
| Hypertension | 45.3 | 38.8 | .043 | 38.5 | 24.8 | <.001 |
| Diabetes | 27.3 | 15.7 | <.001 | 23.5 | 7.8 | <.001 |
| Duration of infection (y) | 34.0 (2.0-56.0) | 31.0 (0-55.0) | <.001 | 23.0 (10.0-52.0) | 23.0 (0-52.0) | .087 |
| Current/past alcohol use | | | | | | | | |
| None/minimal | 36.0 | 38.8 | 69.3 | 73.6 | | | |
| Moderate | 7.6 | 10.1 | 3.9 | 4.7 | | | |
| Heavy | 56.4 | 51.1 | 26.8 | 21.7 | | | |
| Current/past smoking | | | | | | | | |
| Never smoked | 21.4 | 20.8 | 67.6 | 63.5 | | | |
| <10 pack-y | 18.7 | 24.9 | 5.6 | 6.9 | | | |
| 10-20 pack-y | 15.9 | 20.3 | 10.1 | 9.3 | | | |
| >20 pack-y | 44.0 | 34.0 | 16.7 | 20.3 | | | |
| Coffee consumption | 59.1 | 66.5 | .019 | 3.9 | 5.4 | .531 |
| HBsAg+ | 0.4 | 0.0 | .520 | 3.4 | 2.1 | .444 |
| Anti-HBc+ | 34.0 | 29.8 | .169 | 55.3 | 44.3 | .010 |
| Prior HCV treatment | 51.8 | 35.6 | <.001 | 34.6 | 18.8 | <.001 |
| HCV genotype | | | | | | | | |
| 1 | 83.0 | 84.0 | 70.7 | 68.7 | | | |
| 1a | 47.2 | 48.7 | 0.0 | 0.1 | | | |
| 1b | 19.1 | 21.3 | 67.2 | 66.9 | | | |
| 1 not subtyped | 16.7 | 14.0 | 3.5 | 1.7 | | | |
| 2 | 5.3 | 6.6 | 19.9 | 26.6 | | | |
| 3 | 10.0 | 7.2 | 4.7 | 1.7 | | | |
| 4 | 1.5 | 2.1 | 0.0 | 0.0 | | | |
| 5/6/mixed | 0.2 | 0.0 | 4.7 | 3.0 | | | |
| Platelet (<1000/µL) | 93.0 (17.0-409.0) | 201.0 (25.0-559.0) | <.001 | 78.0 (23.0-351.0) | 183.0 (25.0-390.0) | <.001 |
| AST (U/L) | 81.0 (7.2-454.0) | 49.0 (5.9-480.0) | <.001 | 69.0 (20.0-345.0) | 37.0 (11.0-366.0) | <.001 |
| ALT (U/L) | 65.0 (11.0-384.0) | 60.0 (9.0-989.0) | .139 | 54.0 (7.0-344.0) | 60.0 (10.0-488.0) | .002 |
| Total bilirubin (mg/dL) | 1.1 (0.1-12.6) | 0.6 (0.1-2.8) | <.001 | 1.3 (0.4-14.1) | 0.8 (0.3-3.3) | <.001 |
| INR | 1.2 (0.9-3.7) | 1.0 (0.6-3.0) | <.001 | 1.1 (0.8-2.9) | 1.0 (0.8-2.0) | <.001 |
| APRI | 2.3 (0.2-21.9) | 0.6 (0.1-25.6) | <.001 | 2.1 (0.2-33.8) | 0.5 (0.1-40.7) | <.001 |
| APRI >2.0 | 57.4 | 10.9 | <.001 | 52.5 | 5.3 | <.001 |
| FIB-4 | 6.5 (0.3-47.3) | 1.7 (0.3-33.9) | <.001 | 6.8 (0.9-116.7) | 1.7 (0.2-130.3) | <.001 |
| FIB-4 >3.25 | 80.7 | 16.4 | <.001 | 82.7 | 12.5 | <.001 |

Data presented as median (range) for continuous variables or per cent for categorical variables. 
BMI, body mass index; HBsAg, hepatitis B surface antigen; Anti-HBc, antibody to hepatitis B core antigen; HCC, Hepatocellular carcinoma; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalised ratio; APRI, AST to platelet ratio index; FIB-4, fibrosis index based on the 4 factors.
coffee consumption between US patients with and those without advanced liver disease, these differences were not observed in the Chinese cohort.

3.4 | Multivariate analysis of predictors associated with advanced liver disease

Multivariate analyses of predictors associated with advanced liver disease were run after exclusion of patients with ascites. The analysis showed that older age, truncal obesity, diabetes and prior HCV treatment were independently associated with higher likelihood of advanced liver disease in the US cohort while regular coffee consumption was protective (Table 3). Older age, truncal obesity, diabetes and prior HCV treatment were also independently associated with increased risk of advanced liver disease in the Chinese cohort (Table 3). Study site was also a predictor in the Chinese cohort with patients in Gu’an having an odds ratio (OR) of 0.34 of having advanced liver disease compared to those in Beijing.

When data from both cohorts were combined, older age, truncal obesity, diabetes and prior HCV treatment remained significant predictors of advanced liver disease (Table 3). Study site was also a predictor with US patients having higher risk (OR 2.32) while Gu’an patients had lower risk (OR 0.33) of advanced liver disease compared to Beijing patients. Only 5.1% in the Chinese cohort had regular coffee consumption; therefore, coffee consumption was not included in the multivariate analysis of the Chinese cohort and the combined cohort.

Data on duration of infection were missing in 276 patients in US and 237 patients in China; therefore, we did not include duration of infection in the multivariate analysis. In the subgroup with data on duration of infection, duration of infection was independently associated with a higher likelihood of advanced liver disease in the US cohort but not in the Chinese cohort or the combined cohort (Table S2).

3.5 | Later peak in HCV epidemic in China versus US

The markedly higher proportion of US patients with advanced liver disease despite a difference of only 4 years in median age led us to examine the timing of HCV infection in the two cohorts. Time of infection could be estimated in 72.7% of US and 75.5% of Chinese patients. Among these patients, the estimated year at infection in US patients was 10 years earlier, median 1980 vs 1990 in Chinese patients and a significantly higher proportion of US than Chinese patients had an estimated duration of infection ≥30 years (64.1% vs 13.6%, P < .001). Figure 1 shows estimated duration of infection by stage of liver disease in US vs Chinese cohort. Although a significantly higher proportion of patients with advanced liver disease in the US cohort had been infected for longer than 30 years compared to those with no advanced disease: 73.1% vs 54.8%, P < .001; such difference was not observed in the Chinese cohort: 12.9% vs 13.9%.

### TABLE 3

Multivariate analysis of predictors of advanced liver disease (cirrhosis and HCC) in the US cohort, the Chinese cohort and the combined cohorts respectively

| Characteristics                        | Odds ratio (95% confidence interval) | P value |
|----------------------------------------|--------------------------------------|---------|
| **The US cohort**                      |                                      |         |
| Age: each year of increase             | 1.065 (1.045-1.086)                  | <.001   |
| Sex: male vs female                    | 1.322 (0.965-1.812)                  | .083    |
| Obesity by BMI: yes vs no              | 1.713 (0.952-1.976)                  | .090    |
| Truncal obesity: yes vs no             | 1.421 (1.079-2.063)                  | .049    |
| Hypertension: yes vs no                | 0.982 (0.716-1.346)                  | .910    |
| Diabetes: yes vs no                    | 1.520 (1.053-2.193)                  | .025    |
| Coffee consumption: yes vs no          | 0.762 (0.556-0.986)                  | .048    |
| Prior HCV treatment: yes vs no         | 2.003 (1.485-2.701)                  | <.001   |
| **The Chinese cohort**                 |                                      |         |
| Site                                   |                                      |         |
| Gu’an vs Beijing                       | 0.340 (0.214-0.540)                  | <.001   |
| Kuancheng vs Beijing                   | 0.819 (0.428-1.567)                  | .547    |
| Age: each year of increase             | 1.072 (1.049-1.097)                  | <.001   |
| Truncal obesity: yes vs no             | 1.670 (1.113-2.506)                  | .013    |
| Hypertension: yes vs no                | 1.144 (0.740-1.768)                  | .545    |
| Diabetes: yes vs no                    | 2.632 (1.551-4.467)                  | <.001   |
| Anti-HBc: positive vs negative         | 1.031 (0.686-1.549)                  | .885    |
| HCV genotype: 1 vs non 1               | 1.350 (0.833-2.186)                  | .223    |
| Prior HCV treatment: yes vs no         | 1.754 (1.116-2.754)                  | .015    |
| **Combined US and Chinese cohorts**    |                                      |         |
| Site                                   |                                      |         |
| US vs Chinese                          | 2.888 (2.233-3.785)                  | <.001   |
| US vs Beijing                          | 2.321 (1.601-3.358)                  | <.001   |
| Gu’an vs Beijing                       | 0.327 (0.206-0.523)                  | <.001   |
| Kuancheng vs Beijing                   | 0.821 (0.452-1.569)                  | .553    |
| Age: each year of increase             | 1.064 (1.048-1.080)                  | <.001   |
| Sex: male vs female                    | 1.055 (0.820-1.356)                  | .678    |
| Obesity by BMI: yes vs no              | 1.314 (1.032-1.789)                  | .049    |
| Truncal obesity: yes vs no             | 1.530 (1.138-2.056)                  | .005    |
| Hypertension: yes vs no                | 1.037 (0.798-1.348)                  | .784    |
| Diabetes: yes vs no                    | 1.865 (1.357-2.562)                  | <.001   |
| Anti-HBc: positive vs negative         | 1.033 (0.799-1.337)                  | .803    |
| HCV genotype: 1 vs non 1               | 1.003 (0.738-1.364)                  | .984    |
| Prior HCV treatment: yes vs no         | 2.096 (1.622-2.708)                  | <.001   |

Bold values: the factors had statistically significant.
HCC, hepatocellular carcinoma; BMI, body mass index; HCV, hepatitis C virus; Anti-HBc, antibody to hepatitis B core antigen.

Two separate analyses were done for site, (1) with 2 cohorts: US and Chinese, and (2) with 4 sites: US, Gu’an, Kuancheng, and Beijing.

Patients in the US cohort were more likely to have advanced liver disease even after stratification for the estimated duration of infection. The proportion of patients with advanced liver disease in the US and Chinese cohorts was 47.6% vs 21.2% (P < .001) for those with estimated duration of infection 20-30 years, and 58.1% vs
19.4%, respectively ($P < .001$) for those with estimated duration of infection >30 years (Figure 2).

3.6 | Association of obesity and diabetes with advanced liver disease

Truncal obesity and diabetes were independent predictors of advanced liver disease in multivariate analysis of the US and Chinese cohorts in separate as well as in combined analysis. Obesity, truncal obesity and diabetes were significantly more prevalent in US than in Chinese patients. Diabetes remained more prevalent in US patients even after stratification by BMI, waist circumference, and age (except for those <45 years). However, when analysis was stratified by liver disease severity, diabetes was more common only in US patients without cirrhosis (15.7% vs 7.8%, $P < .001$) and not in those with cirrhosis or HCC. (Table 4)

4 | DISCUSSION

Chronic HCV infection is the leading cause of cirrhosis and HCC in the US, but it accounts for a smaller per cent of cirrhosis and HCC in China even though the prevalence of chronic HCV infection in the two countries is not substantially different. Our study sought to
determine whether Chinese patients with chronic HCV infection have less advanced liver disease than American patients and to identify the reasons contributing to the discrepancy. We found that American patients had more advanced liver disease than Chinese patients despite a difference in median age of only 4 years.

Our finding could potentially be related to under-diagnosis of cirrhosis or HCC in the Chinese cohort; however, both teams followed the same protocol and manual of procedures and underwent training together prior to the start of the study. Furthermore, criteria for diagnosis of cirrhosis and HCC were pre-defined and source documents used to support these diagnoses were audited. Our finding could also be related to differences in clinical setting in which the patients were enrolled. The US cohort was enrolled from a tertiary liver centre, which has a large liver transplant programme and a multi-disciplinary liver tumour clinic but this was also true for the Beijing site, and a statistically significant difference in proportion of patients with advanced liver disease persisted when comparisons were limited to US and Beijing sites. We acknowledge that differences in clinical setting can influence our results. Indeed, referral bias is the most likely reason why Gu’an patients were least likely to have advanced disease because majority of the Gu’an patients were diagnosed to have HCV infection during investigations of outbreaks of hepatitis C while most patients at the other sites presented with liver disease. Patients in Gu’an and Kuancheng sites also differed in that most were peasants while patients in Beijing site were mainly white collar workers. Differences in lifestyle, diet and physical activity likely explain why diabetes is more common among Beijing patients than Gu’an and Kuancheng patients.

Many other differences in the two cohorts may have contributed to the higher prevalence of advanced disease in the US cohort, eg, more men, and more patients with history of regular alcohol or tobacco use. However, alcohol and tobacco use were not predictors of advanced disease in the US, Chinese, or combined cohort. Male sex had been shown in many studies to be a predictor of advanced liver disease.11,20 We confirmed this to be the case in the US cohort but this was not the case for the Chinese cohort.

The peak of the HCV epidemic in the US occurred in the 1970s while the peak in China is believed to have occurred in the 1980s.5,21 In our study, among the patients in whom we could estimate the time of infection, median year at infection was 10 years earlier in the US cohort. However, whereas US patients with longer duration of infection had more advanced disease, this was not apparent in the Chinese cohort. When we stratified patients by estimated duration of infection, US patients had more advanced disease compared to Chinese patients in each stratum and the difference became more marked as the estimated duration of infection increased although the number of Chinese patients with estimated duration of infection longer than 30 years was small. Multivariate analysis of the subgroup with data on estimated duration of infection showed that duration of infection was an independent predictor of advanced disease in the US cohort but not in the Chinese cohort. Our findings suggest that HCV-related liver disease may progress more slowly in Chinese patients compared to American patients.

Two other factors were different in the two cohorts: lower prevalence of anti-HBc and more frequent coffee consumption in the US cohort, but these would have predicted less advanced liver disease in the US cohort. We found a higher prevalence of anti-HBc in patients with advanced disease but the difference was statistically significant only in the Chinese cohort. Coffee consumption had been demonstrated to have a protective effect against liver disease including HCC.13,14,22 US patients were more likely to drink coffee and regular coffee consumption was associated with less advanced liver disease in the US cohort. Very few Chinese patients regularly drink coffee; thus, it was not possible to determine if coffee consumption also had a protective effect on HCV-related liver disease in Chinese patients.

The most consistent predictors of advanced disease in both cohorts were truncal obesity and diabetes. Obesity and diabetes had been shown to be associated with increased risk of cancers including liver cancers.11,23-25 Obesity and diabetes can contribute to hepatic steatosis which in turn has been shown to accelerate fibrosis progression in patients with hepatitis C.26,27 In this study, diabetes was more common in patients with cirrhosis and those with HCC. When we stratified for liver disease stage, prevalence of diabetes was higher in US than Chinese patients only in patients with no cirrhosis but this was not the case for the Chinese cohort. We hypothesise that our finding of more advanced disease in the US cohort may be explained by a higher prevalence of concomitant nonalcoholic fatty liver disease, which accelerates the development of cirrhosis and HCC. Our finding highlights the importance of treating both hepatitis C and

| TABLE 4 Prevalence of diabetes by age, sex, obesity and liver disease severity |
|------------------|------------------|------------------|------------------|
| US (n/N, %)      | China (n/N, %)   | P value          |
| Age (yr)         |                  |                  |
| <45              | 3/101 (3.0)      | 9/191 (4.7)      | .687             |
| 45-60            | 145/627 (23.1)   | 67/574 (11.7)    | <.001            |
| >60              | 70/272 (25.7)    | 27/192 (14.1)    | .003             |
| Sex              |                  |                  |
| Male             | 146/614 (23.8)   | 50/464 (10.8)    | <.001            |
| Female           | 72/386 (18.7)    | 53/493 (10.8)    | .001             |
| BMI              |                  |                  |
| Normal           | 38/256 (14.8)    | 39/451 (8.6)     | .016             |
| Overweight       | 70/353 (19.8)    | 49/343 (14.3)    | .066             |
| Obese            | 109/384 (28.4)   | 14/161 (8.7)     | <.001            |
| Truncal obesity  |                  |                  |
| No               | 58/341 (17.0)    | 42/531 (7.9)     | <.001            |
| Yes              | 147/598 (24.6)   | 59/423 (13.9)    | <.001            |
| Liver disease category |            |                  |
| No cirrhosis     | 75/477 (15.7)    | 61/778 (7.8)     | <.001            |
| Cirrhosis        | 106/382 (27.7)   | 32/153 (20.9)    | .128             |
| HCC              | 37/141 (26.2)    | 10/26 (38.5)     | .300             |

BMI, body mass index; HCC, hepatocellular carcinoma.
concomitant fatty liver. Indeed, one study of 96 patients with HBV-related cirrhosis who had maintained virus suppression after 5 years of tenofovir therapy showed that obesity and diabetes mellitus were significantly more common in patients who failed to have regression of cirrhosis on repeat liver biopsy compared to those who did.28

Our study is unique in the use of an identical protocol, structured interviews and uniform data collection in two parallel cohorts of patients and the strict adherence to pre-defined criteria for cirrhosis and HCC. There are, however, several limitations. While this study enrolled nearly 2000 patients, the number is too small to represent all patients with chronic HCV infection in the US and in China. Furthermore, patients in the US were enrolled from only one tertiary liver centre and the findings may not be generalised to other US patients. Indeed, we observed differences in patient characteristics and stage of liver disease in the three Chinese sites. Nonetheless, significant difference in liver disease stage was observed between the US and Beijing sites despite similarities in clinical setting.

In summary, our study found a higher per cent of US patients with chronic HCV infection had cirrhosis or HCC compared to Chinese patients even among patients with similar estimated duration of infection. We believe that a higher prevalence of concomitant fatty liver in the US patients may be a major contributor to this observed difference. Our findings if confirmed highlight that management of glycometabolic abnormalities should go hand in hand with anti-viral treatment for patients with chronic hepatitis C and concomitant obesity or diabetes.

ACKNOWLEDGEMENTS

Declaration of personal interests: R.J.F. has received research grants from Bristol-Myers Squibb, Gilead and Janssen. A.S.L. has received research grants from AbbVie, Bristol-Myers Squibb, Gilead, Idenix and Merck and had served as an advisor for Gilead. L.W. has received research grants from Roche and Bristol-Myers Squibb and has served as an advisor for Gilead and Abbott. H.R., E.W., S.F., M.Y., B.F., A.L. and R.F. have no conflict of interests to disclose.

AUTHORSHIP

Guarantor of the article: Prof. L. Wei.

Author contributions: H.R., A.S.L. and L.W. designed the study, performed data analysis, and wrote and edited the manuscript. R.J.F. contributed to design of the study and editing of the manuscript. H.R., E.W., S.F., M.Y. and B.F. enrolled the patients and collected data and samples for the study. E.W., S.F. and A.L. contributed to the design of the database and data analyses. R.F. performed testing of research samples. All authors reviewed and approved the manuscript. All authors approved the final version of the manuscript.

REFERENCES

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095-2128.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-1342.
3. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31:61-80.
4. Duan Z, Jia JD, Hou J, et al. Current challenges and the management of chronic hepatitis C in mainland China. J Clin Gastroenterol. 2014;48:679-686.
5. De Martel C, Mauclerc-Bouch D, Plummer M, Franceschi S. Worldwide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62:1190-1200.
6. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-2219.
7. Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 2009;29:589-599.
8. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148.
9. Rao HY, Sun DG, Yang RF, et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19 year cohort study. J Gastroenterol Hepatol. 2012;27:526-532.
10. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:558-568.
11. Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734.
12. Bravi F, Bosetti C, Tavani A, et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1413-1421.
13. Lai GY, Weinstein SJ, Albanes D, et al. The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer. 2013;109:1344-1351.
14. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
15. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37:S1-S116.
16. Chinese Diabetes Society. China guideline for type 2 diabetes-2010. Beijing: Peking University Medical Press; 2011.
17. Diao T, Sun X, Yin P, et al. Increasing trends in central obesity among Chinese adults with normal body mass index, 1993-2009. BMC Public Health. 2013;13:327.
18. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
19. Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099-2108.
20. White DL, Tavakoli-Tabasi S, Kuzniarek J, et al. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012;55:759-768.
21. Gao X, Cui Q, Shi X, et al. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infect Dis. 2011;11:88.
22. Carreno V. Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy. Aliment Pharmacol Ther. 2014;39:148-162.
23. Arnold M, Leitzmann M, Freisling H, et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 2016;41:8-15.
24. Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. *Dig Dis Sci.* 2016;61:636-645.

25. Huang YW, Wang TC, Yang SS, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study. *Aliment Pharmacol Ther.* 2015;42:902-911.

26. Dyal HK, Aguilar M, Bhuket T, et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review. *Dig Dis Sci.* 2015;60:2813-2824.

27. Goossens N, Negro F. The impact of obesity and metabolic syndrome on chronic hepatitis C. *Clin Liver Dis.* 2014;18:147-156.

28. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet.* 2013;381:468-475.

---

**SUPPORTING INFORMATION**

Additional Supporting Information will be found online in the supporting information tab for this article.

*How to cite this article:* Rao H, Wu E, Fu S, et al. The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease. *Aliment Pharmacol Ther.* 2017;46:731–740. [https://doi.org/10.1111/apt.14273](https://doi.org/10.1111/apt.14273)